1. Amsterdam JD, García-España F, Rybakowski J. Rates of flu-like infection in patients with affective illness. J Affect Disord 1998: 177-182.
2.
Bonnet U, Juckel G. COVID-19 outcomes: Does the use of psychotropic drugs make a difference? Accumulating evidence of a beneficial effect of antidepressants-a scoping review. J Clin Psychopharmacol 2022; 42: 284-292.
3.
Brenner SR. The potential of memantine and related adamantanes such as amantadine, to reduce the neurotoxic effects of COVID-19, including ARDS and to reduce viral replication through lysosomal effects. J Med Virol 2020; 92: 2341-2342.
4.
Butler M, Cross B, Hafeez D, Lim MF, Morrin H, Rengasamy ER et al. Emerging knowledge of the neurobiology of COVID-19. Psychiatr Clin North Am 2022; 45: 29-43.
5.
Canal-Rivero M, Catalán-Barragán R, Rubio-García A, Garrido-Torres N, Crespo-Facorro B, Ruiz-Veguilla M; IBIS Translational Psychiatry Group. Lower risk of SARS-CoV-2 infection in individuals with severe mental disorders on antipsychotic treatment: A retrospective epidemiological study in a representative Spanish population. Schizophr Res 2021; 229: 53-54. (a)
6.
Canal-Rivero M, Catalán-Barragán R, Rubio-García A, Garrido-Torres N, Crespo-Facorro B, Ruiz-Veguilla M; IBIS Translational Psychiatry Group. The role of antipsychotics against COVID-19: A topic for debate. Schizophr Res 2021; 235: 5-6. (b)
7.
Clelland CL, Ramiah K, Steinberg L, Clelland JD. Analysis of the impact of antidepressants and other medications on COVID-19 infection risk in a chronic psychiatric in-patient cohort. BJPsych Open 2021; 8: e6.
8.
Collazos J, Domingo P, Fernández-Araujo N, Asensi-Díaz E, Vilchez-Rueda H, Lalueza A et al. Exposure to valproic acid is associated with less pulmonary infiltrates and improvements in diverse clinical outcomes and laboratory parameters in patients hospitalized with COVID-19. PLoS One 2022; 17: e0262777.
9.
Cortés-Borra A, Aranda-Abreu GE. Amantadine in the prevention of clinical symptoms caused by SARS-CoV-2. Pharmacol Rep 2021 Jun; 73(3): 962-965.
10.
Dalwadi DA, Kim S, Schetz JA. Activation of the sigma-1 receptor by haloperidol metabolites facilitates brain-derived neurotrophic factor secretion from human astroglia. Neurochem Int 2017; 105: 21-31.
11.
De Picker LJ, Leboyer M, Geddes JR, Morrens M, Harrison PJ, Taquet M. Association between serum lithium level and incidence of COVID-19 infection. Br J Psychiatry 2022 Mar 23: 1-3; doi: 10.1192/bjp.2022.42. Online ahead of print.
12.
Dechaumes A, Nekoua MP, Belouzard S, Sane F, Engelmann I, Dubuisson J et al. Fluoxetine can inhibit SARS-CoV-2 in vitro. Microorganisms 2021; 9: 339.
13.
Facente SN, Reiersen AM, Lenze EJ, Boulware DR, Klausner JD. Fluvoxamine for the early treatment of SARS-CoV-2 infection: A review of current evidence. Drugs 2021; 81: 2081-2089.
14.
Fillmore N, Bell S, Shen C, Nguyen V, La J, Dubreuil M et al. Disulfiram use is associated with lower risk of COVID-19: A retrospective cohort study. PLoS One 2021; 16: e0259061.
15.
Fink K, Nitsche A, Neumann M, Grossegesse M, Eisele KH, Danysz W. Amantadine inhibits SARS-CoV-2 in vitro. Viruses 2021; 13: 539.
16.
Gattner K, Rybakowski J. Ciężki przebieg COVID-19 u pacjenta leczonego profilaktycznie litem. Farmakoter Psychiatr Neurol 2020; 36: 143-148.
17.
Gorostowicz A, Dudek D, Siwek M. List do redakcji. Terapia litem jako czynnik chroniący przed zakażeniem wirusem SARS-CoV-2? Obserwacje z ogniska epidemicznego Psychiatr Pol 2022; 56: 417-422.
18.
Hashimoto K. Repurposing of CNS drugs to treat COVID-19 infection: targeting the sigma-1 receptor. Eur Arch Psychiatry Clin Neurosci 2021; 271: 249-258.
19.
Hashimoto Y, Suzuki T, Hashimoto K. Old drug fluvoxamine, new hope for COVID-19. Eur Arch Psychiatry Clin Neurosci 2022; 272: 161-163.
20.
Hoertel N, Sánchez-Rico M, Vernet R, Jannot AS, Neuraz A, Blanco C et al. Observational study of chlorpromazine in hospitalized patients with COVID-19. Clin Drug Investig 2021; 41: 221-233. (a)
21.
Hoertel N, Sánchez-Rico M, Vernet R, Jannot AS, Neuraz A, Blanco C et al. Observational study of haloperidol in hospitalized patients with COVID-19. PLoS One 2021; 16: e0247122. (b)
22.
Hoertel N, Sánchez-Rico M, Vernet R, Beeker N, Jannot AS, Neuraz A et al. Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19: results from an observational study. Mol Psychiatry 2021; 26: 5199-5212. (c)
23.
Jaracz J, Rybakowski J. Fluwoksamina – najdłużej stosowany lek z grupy selektywnych inhibitorów wychwytu serotoniny. Farmakoter Psychiatr Neurol 2006; 22: 167-175.
24.
Kessler RC, Chiu WT, Hwang IH, Puac-Polanco V, Sampson NA, Ziobrowski HN et al. Changes in prevalence of mental Illness among US adults during compared with before the COVID-19 pandemic. Psychiatr Clin North Am 2022; 45: 1-28.
25.
Koenders M, Mesbah R, Spijker A, Boere E, de Leeuw M, van Hemert B et al. Effects of the COVID-19 pandemic in a preexisting longitudinal study of patients with recently diagnosed bipolar disorder: Indications for increases in manic symptoms. Brain Behav 2021; 11: e2326.
26.
Kurczewska E, Nawojczyk M, Ferensztajn-Rochowiak E, Jaracz J, Rybakowski F. Onset of bipolar disorder induced by treated COVID-19 infection in a 44-year-old man with no psychiatric history. Bipolar Disord 2022 Mar; 24(2): 214-216.
27.
Lee TC, Vigod S, Bortolussi-Courval É, Hanula R, Boulware DR, Lenze EJ et al. Fluvoxamine for outpatient management of COVID-19 to prevent hospitalization: A systematic review and meta-analysis. JAMA Netw Open 2022; 5: e226269.
28.
Lenze EJ, Mattar C, Zorumski CF, Stevens A, Schweiger J, Nicol GE et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: A randomized clinical trial. JAMA 2020; 324: 2292-2300.
29.
Lenze EJ, Reiersen AM, Santosh PJ. Repurposing fluvoxamine, and other psychiatric medications, for COVID-19 and other conditions. World Psychiatry 2022; 21: 314-315.
30.
Lieb J. Remission of recurrent herpes infection during therapy with lithium. N Eng J Med 1979; 301: 942.
31.
Malinowska B, Baranowska-Kuczko M, Kicman A, Schlicker E. Opportunities, challenges and pitfalls of using cannabidiol as an adjuvant drug in COVID-19. Int J Mol Sci 2021; 22: 1986.
32.
Mazza MG, Zanardi R, Palladini M, Rovere-Querini P, Benedetti F. Rapid response to selective serotonin reuptake inhibitors in post-COVID depression. Eur Neuropsychopharmacol 2022; 54: 1-6.
33.
Moreno-Pérez O, Merino E, Ramos JM, Rodríguez JC, Diaz C, Mas P et al. Valproic acid could help in the fight against COVID-19: a case-control study. Neurologia 2022 Feb 14; doi: 10.1016/j.nrl.2022.01.007. Online ahead of print.
34.
Mueller JK, Riederer P, Müller WE. Neuropsychiatric drugs against COVID-19: what is the clinical evidence? Pharmacopsychiatry 2022; 55: 7-15.
35.
Murru A, Manchia M, Hajek T, Nielsen RE, Rybakowski JK, Sani G et al. Lithium’s antiviral effects: a potential drug for COVID-19 disease? Int J Bipolar Disord 2020; 8: 21.
36.
Nemani K, Williams SZ, Olfson M, Leckman-Westin E, Finnerty M, Kammer J et al. Association between the use of psychotropic medications and the risk of COVID-19 infection among long-term inpatients with serious mental illness in a New York State-wide psychiatric hospital system. JAMA Netw Open 2022; 5: e2210743.
37.
Nguyen LC, Yang D, Nicolaescu V, Best TJ, Gula H, Saxena D et al. Cannabidiol inhibits SARS-CoV-2 replication through induction of the host ER stress and innate immune responses. Sci Adv. 2022 Feb 25; 8: eabi6110. doi: 10.1126/sciadv.abi6110. Epub ahead of print.
38.
Nowak JK, Walkowiak J. Lithium and coronavirus infections. A scoping review. F1000Research 2020; 9: 93.
39.
Qaswal AB, Guzu H, Suleiman A, Atiyat B. The potential role of lithium as an antiviral agent against SARS-CoV-2 via membrane depolarization: review and hypothesis. Sci Pharm 2021; 89; 11.
40.
Pardamean E, Roan W, Iskandar KTA, Prayangga R, Hariyanto TI. Mortality from coronavirus disease 2019 (COVID-19) in patients with schizophrenia: A systematic review, meta-analysis and meta-regression. Gen Hosp Psychiatry 2022; 75: 61-67.
41.
Park MH, Kwon DY. A retrospective review of memantine use and COVID-19-associated mortality from a national database. J Med Virol 2021; 93: 168-169.
42.
Pitt B, Sutton NR, Wang Z, Goonewardena SN, Holinstat M. Potential repurposing of the HDAC inhibitor valproic acid for patients with COVID-19. Eur J Pharmacol 2021; 898: 173988.
43.
Plaze M, Attali D, Prot M, Petit AC, Blatzer M, Vinckier F et al. Inhibition of the replication of SARS-CoV-2 in human cells by the FDA-approved drug chlorpromazine. Int J Antimicrob Agents 2021; 57: 106274.
44.
Rajkumar RP. Lithium as a candidate treatment for COVID-19: Promises and pitfalls. Drug Dev Res 2020; 81: 782-785.
45.
Ramlall V, Zucker J, Tatonetti N. Melatonin is significantly associated with survival of intubated COVID-19 patients. medRxiv 2020: 2020.10.15.20213546.
46.
Reis G, Dos Santos Moreira-Silva EA, Silva DCM, Thabane L, Milagres AC, Ferreira TS et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Glob Health 2022; 10: e42-e51.
47.
Rejdak K, Fiedor P, Bonek R, Goch A, Gala-Błądzińska A, Chełstowski W et al. The use of amantadine in the prevention of progression and treatment of COVID-19 symptoms in patients infected with the SARS-CoV-2 virus (COV-PREVENT): Study rationale and design. Contemp Clin Trials 2022; 116: 106755.
48.
Rudd CE. Commentary: Does lithium deserve a place in the treatment against COVID-19? A preliminary observational study in six patients, case report. Front Pharmacol 2020; 11: 613734. (b)
49.
Rudd CE. GSK-3 inhibition as a therapeutic approach against SARs CoV2: Dual benefit of inhibiting viral replication while potentiating the immune response. Front Immunol 2020; 11: 1638. (a)
50.
Rybakowski J. Informacja dotycząca stosowania litu w okresie pandemii COVID-19. Psychiatra 2020; 28: 48-49.
51.
Rybakowski J. Występowanie zakażenia COVID-19 u 50 pacjentów otrzymujących lit. Farmakoter Psychiatr Neurol 2021; 37: 113-121.
52.
Rybakowski JK, Amsterdam JD. Lithium prophylaxis and recurrent labial herpes infections. Lithium 1991; 2: 43-47.
53.
Sabe M, Dorsaz O, Huguelet P, Kaiser S. Toxicity of psychotropic drugs in patients with COVID-19: A systematic review. Gen Hosp Psychiatry 2021; 70: 1-9
54.
Sánchez-Rico M, Limosin F, Vernet R, Beeker N, Neuraz A, Blanco C et al. Hydroxyzine use and mortality in patients hospitalized for COVID-19: A multicenter observational study. J Clin Med 2021;10: 5891.
55.
Skinner G.R.B., Hartley C., Buchan A., Harper L, Gallimore P. The effect of lithium chloride on the replication of herpes simplex virus. Med Microbiol Immunol 1980; 168: 258-265.
56.
Spuch C, López-García M, Rivera-Baltanás T, Rodrígues-Amorím D, Olivares JM. Does lithium deserve a place in the treatment against COVID-19? A preliminary observational study in six patients, case report. Front Pharmacol 2020; 11: 557629.
57.
Suwanwongse K, Shabarek N. Lithium toxicity in two coronavirus disease 2019 (COVID-19) patients. Cureus 2020; 12: e8384.
58.
Szkaradkiewicz A. Nowe koronawirusy człowieka – SARS-CoV, MERS-CoV i 2019-nCoV (COVID-19). Zakażenia XXI Wieku 2020; 1: 1.
59.
Wen W, Chen C, Tang J, Wang C, Zhou M, Cheng Y et al. Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19: a meta-analysis. Ann Med 2022; 54: 516-523.
60.
Wichniak A, Kania A, Siemiński M, Cubała WJ. Melatonin as a potential adjuvant treatment for COVID-19 beyond sleep disorders. Int J Mol Sci. 2021; 22: 8623.
61.
Zhang R, Wang X, Ni L, Di X, Ma B, Niu S et al. COVID-19: Melatonin as a potential adjuvant treatment. Life Sci 2020; 250: 117583.
